## Cédric Garcia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7930989/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impedance-based sensors discriminate among different types of blood thrombi with very high specificity and sensitivity. Journal of NeuroInterventional Surgery, 2023, 15, 526-531.	3.3	3
2	Occurrence of a paroxysmal nocturnal hemoglobinuria clone in an essential thrombocythemia: a link between <i>PIGV</i> and <i>MPL</i> . Haematologica, 2022, 107, 1989-1993.	3.5	2
3	Evolution of platelet activation parameters during septic shock in intensive care unit. Platelets, 2022, 33, 918-925.	2.3	7
4	Platelet activation and partial desensitization are associated with viral xenophagy in patients with severe COVID-19. Blood Advances, 2022, 6, 3884-3898.	5.2	12
5	Absence of susceptibility vessel sign is associated with aspiration-resistant fibrin/platelet-rich thrombi. International Journal of Stroke, 2021, 16, 972-980.	5.9	14
6	Effects of novel Btk and Syk inhibitors on platelet functions alone and in combination in vitro and in vivo. Journal of Thrombosis and Haemostasis, 2020, 18, 3336-3351.	3.8	8
7	Thromboembolic events and Covid-19. Advances in Biological Regulation, 2020, 77, 100735.	2.3	61
8	Platelet function defects and sertralineâ€induced bleeding: a case report. Fundamental and Clinical Pharmacology, 2020, 34, 632-636.	1.9	2
9	Platelets Are Critical Key Players in Sepsis. International Journal of Molecular Sciences, 2019, 20, 3494.	4.1	105
10	Kinetics of mean platelet volume predicts mortality in patients with septic shock. PLoS ONE, 2019, 14, e0223553.	2.5	17
11	Catalytic dysregulation of SHP2 leading to Noonan syndromes affects platelet signaling and functions. Blood, 2019, 134, 2304-2317.	1.4	23
12	Platelet Activation Is Limited during Transcatheter Aortic Valve Implantation in Patients on Aspirin Monotherapy and without per Procedural Clinical Complications. TH Open, 2019, 03, e146-e152.	1.4	0
13	Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions. Haematologica, 2019, 104, 2292-2299.	3.5	39
14	First description of an IgM monoclonal antibody causing αllbβ3 integrin activation and acquired Glanzmann thrombasthenia associated with macrothrombocytopenia. Journal of Thrombosis and Haemostasis, 2019, 17, 795-802.	3.8	6
15	Deciphering biased inverse agonism of cangrelor and ticagrelor at P2Y12 receptor. Cellular and Molecular Life Sciences, 2019, 76, 561-576.	5.4	20
16	Predictive Value of Susceptibility Vessel Sign for Arterial Recanalization and Clinical Improvement in Ischemic Stroke. Stroke, 2019, 50, 512-515.	2.0	33
17	Acute coronary syndrome remodels the antiplatelet aggregation properties of HDL particle subclasses. Journal of Thrombosis and Haemostasis, 2018, 16, 933-945.	3.8	9
18	Platelet activation and prothrombotic properties in a mouse model of peritoneal sepsis. Scientific Reports, 2018, 8, 13536.	3.3	44

CéDRIC GARCIA

#	Article	IF	CITATIONS
19	Effect of estetrol, a selective nuclear estrogen receptor modulator, in mouse models of arterial and venous thrombosis. Molecular and Cellular Endocrinology, 2018, 477, 132-139.	3.2	28
20	δ-storage pool disease: an underestimated cause of unexplained bleeding. Hematologie, 2017, 23, 243-254.	0.0	4
21	Effect of chronic estradiol plus progesterone treatment on experimental arterial and venous thrombosis in mouse. PLoS ONE, 2017, 12, e0177043.	2.5	14
22	The class I phosphoinositide 3-kinases $\hat{I}\pm$ and $\hat{I}^2$ control antiphospholipid antibodies-induced platelet activation. Thrombosis and Haemostasis, 2016, 115, 1138-1146.	3.4	13
23	ATPâ€binding cassette transporter 1 (ABCA1) deficiency decreases platelet reactivity and reduces thromboxane A2 production independently of hematopoietic ABCA1. Journal of Thrombosis and Haemostasis, 2016, 14, 585-595.	3.8	12
24	Platelet activation and arterial peripheral serotonin turnover in cardiac remodeling associated to aortic stenosis. American Journal of Hematology, 2015, 90, 15-19.	4.1	26
25	Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia, 2015, 29, 783-787.	7.2	191
26	Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: Comparative effects of prasugrel and ticagrelor on platelet reactivity. International Journal of Cardiology, 2014, 174, 874-876.	1.7	15
27	lbrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood, 2014, 124, 3991-3995.	1.4	265
28	Elucidation of Mild Bleeding Disorders Reported Under Ibrutinib (Imbruvica(R)) Therapy: Implications for Optimal Clinical Management. Blood, 2014, 124, 3296-3296.	1.4	5
29	Switching patients from clopidogrel to prasugrel in acute coronary syndrome: effects of prasugrel loading dose on residual platelet reactivity. Journal of Thrombosis and Haemostasis, 2012, 10, 1946-1949.	3.8	10
30	The Sykâ€kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparinâ€PF4 complex directed antibodies. Journal of Thrombosis and Haemostasis, 2011, 9, 2067-2076.	3.8	42
31	Targeted drug therapy: The platelet side. Platelets, 2011, 22, 479-484.	2.3	5
32	Assessment of platelet response to clopidogrel through measurement of ADP-induced Akt phosphorylation. Journal of Thrombosis and Haemostasis, 2009, 7, 1411-1413.	3.8	2
33	The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood, 2009, 114, 1884-1892.	1.4	110